Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Gasche, C; Waldhoer, T; Feichtenschlager, T; Male, C; Mayer, A; Mittermaier, C; Petritsch, W; Austrian Inflammatory Bowel Diseases Study Group.
Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia.
Am J Gastroenterol. 2001; 96(8):2382-2387
Doi: 10.1111/j.1572-0241.2001.04094.x
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Petritsch Wolfgang
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- OBJECTIVE: Inflammatory bowel disease (IBD)-associated anemia responds to i.v. iron therapy. However, because of concurrent chronic inflammation, some patients do not respond adequately. Erythropoietin therapy has been shown to be effective in the latter cohort. Our goal was to find parameters that can predict the effectiveness of iron sucrose in IBD-associated anemia. METHODS: One hundred three patients with severe IBD-associated anemia (Hb less than or equal to 10.5 g/dl) were treated prospectively for 4 wk with iron sucrose (total iron dose = 1.2 g) in an open label, multicenter trial. Treatment response was defined as an increase in Hb of greater than or equal to2.0 g/dl. A logistic regression analysis was performed with treatment response as the dependent variable and the following independent variables: serum erythropoietin, mean corpuscular Hb, transferrin, ferritin, soluble transferrin receptor (sTfR), C-reactive protein, interleukin 6 (IL-6), and disease activity. RESULTS: Sixty-seven of 103 patients (65%) responded to iron sucrose. From the variables under investigation, erythropoietin, sTfR, transferrin, and IL-6 were significantly associated with treatment response. The R-2 values showed that erythropoietin (8.0%), sTfR (11.4%), and transferrin (10.4%), but not IL-6 (1.3%), contribute a relevant amount of information to the model. An estimated 80% probability of treatment response was found at erythropoietin levels of > 166 U/L, sTfR levels of > 75 nmol/L, or transferrin levels of >3.83 g/L. CONCLUSIONS: Serum erythropoietin, STIR, and transferrin concentrations have the potential to predict the response to iron sucrose therapy in IBD-associated anemia. These parameters may help to identify individuals who benefit the most from additional erythropoietin treatment. (C) 2001 by Am. Coll. of Gastroenterology.
- Find related publications in this database (using NLM MeSH Indexing)
- Anemia, Iron-Deficiency - drug therapy Anemia, Iron-Deficiency - etiology
- Enzyme-Linked Immunosorbent Assay -
- Erythropoietin - metabolism Erythropoietin - therapeutic use
- Female -
- Ferric Compounds - therapeutic use
- Humans -
- Inflammatory Bowel Diseases - complications
- Interleukin-6 - metabolism
- Logistic Models -
- Male -
- Prospective Studies -
- ROC Curve -
- Receptors, Transferrin - metabolism
- Sensitivity and Specificity -
- Transferrin - metabolism
- Treatment Outcome -